Cyclic guanosine monophosphate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cyclic guanosine monophosphate
CGMP2.svg
Identifiers
CAS number 7665-99-8 YesY
PubChem 24316
ChemSpider 22734 YesY
MeSH Cyclic+GMP
ChEBI CHEBI:16356 YesY
ChEMBL CHEMBL395336 YesY
IUPHAR ligand 2347
Jmol-3D images Image 1
Properties
Molecular formula C10H12N5O7P
Molar mass 345.21 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references

Cyclic guanosine monophosphate (cGMP) is a cyclic nucleotide derived from guanosine triphosphate (GTP). cGMP acts as a second messenger much like cyclic AMP. Its most likely mechanism of action is activation of intracellular protein kinases in response to the binding of membrane-impermeable peptide hormones to the external cell surface.[1]

Synthesis[edit]

Guanylate cyclase (GC) catalyzes cGMP synthesis. This enzyme converts GTP to cGMP. In turn, peptide hormones such as the atrial natriuretic factor activate membrane-bound GC, while soluble GC is typically activated by nitric oxide to stimulate cGMP synthesis.

Effects[edit]

cGMP is a common regulator of ion channel conductance, glycogenolysis, and cellular apoptosis. It also relaxes smooth muscle tissues. In blood vessels, relaxation of vascular smooth muscles lead to vasodilation and increased blood flow.

cGMP is a secondary messenger in phototransduction in the eye. In the photoreceptors of the mammalian eye, the presence of light activates phosphodiesterase, which degrades cGMP. The sodium ion channels in photoreceptors are cGMP-gated, so degradation of cGMP causes sodium channels to close, which leads to the hyperpolarization of the photoreceptor's plasma membrane and ultimately to visual information being sent to the brain.[2]

cGMP is also seen to mediate the switching on of the attraction of apical dendrites of pyramidal cells in cortical layer V towards semaphorin-3A (Sema3a).[3] Whereas the axons of pyramidal cells are repelled by Sema3a, the apical dendrites are attracted to it. The attraction is mediated by the increased levels of soluble guanylate cyclase (SGC) that are present in the apical dendrites. SGC generates cGMP, leading to a sequence of chemical activations that result in the attraction towards Sema3a. The absence of SGC in the axon causes the repulsion from Sema3a. This strategy ensures the structural polarization of pyramidal neurons and takes place in embryonic development.

cGMP, like cAMP, gets synthesized when olfactory receptors receive odorous input. cGMP is produced slowly and has a more sustained life than cAMP, which has implicated it in long-term cellular responses to odor stimulation, such as long-term potentiation cGMP in the olfactory is synthesized by both membrane guanylyl cylcase (mGC) as well as soluble guanylyl cyclase (sGC). Studies have found that cGMP synthesis in the olfactory is due to sGC activation by nitric oxide, a neurotransmitter. cGMP also requires increased intracellular levels of cAMP and the link between the two second messengers appears to be due to rising intracellular calcium levels.[4]

Degradation[edit]

Numerous cyclic nucleotide phosphodiesterases (PDE) can degrade cGMP by hydrolyzing cGMP into 5'-GMP. PDE 5, -6 and -9 are cGMP-specific while PDE1, -2, -3, -10 and -11 can hydrolyse both cAMP and cGMP.

Phosphodiesterase inhibitors prevent the degradation of cGMP, thereby enhancing and/or prolonging its effects. For example, Sildenafil (Viagra) and similar drugs enhance the vasodilatory effects of cGMP within the corpus cavernosum by inhibiting PDE 5 (or PDE V). This is used as a treatment for erectile dysfunction. However, the drug can inhibit PDE6 in retina (albeit with less affinity than PDE5). This has been shown to result in loss of visual sensitivity but is unlikely to impair common visual tasks, except under conditions of reduced visibility when objects are already near visual threshold.[5] This effect is largely avoided by other PDE5 inhibitors, such as tadalafil.[6]

Protein kinase activation[edit]

cGMP is involved in the regulation of some protein-dependent kinases. For example, PKG (protein kinase G) is a dimer consisting of one catalytic and one regulatory unit, with the regulatory units blocking the active sites of the catalytic units.

cGMP binds to sites on the regulatory units of PKG and activates the catalytic units, enabling them to phosphorylate their substrates. Unlike with the activation of some other protein kinases, notably PKA, the PKG is activated but the catalytic and regulatory units do not disassociate.

References[edit]

  1. ^ Francis SH, Corbin JD (August 1999). "Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action". Crit Rev Clin Lab Sci 36 (4): 275–328. doi:10.1080/10408369991239213. ISSN 1040-8363. PMID 10486703. 
  2. ^ R. Lane Brown, Timothy Strassmaier, James D. Brady, Jeffrey W. Karpen (2006). "The Pharmacology of Cyclic Nucleotide-Gated Channels: Emerging from the Darkness". Current Pharmaceutical Design 12 (28): 3597–613. doi:10.2174/138161206778522100. PMC 2467446. PMID 17073662. NIHMSID: NIHMS47625. 
  3. ^ Franck Polleux, Theresa Morrow, Anirvan Ghosh (April 2000). "Semaphorin 3A is a chemoattractant for cortical apical dendrites". Nature 404 (6778): 567–73. doi:10.1038/35007001. PMID 10766232. 
  4. ^ Pietrobon M., Zampara I., Maritan M., Franchi S., Pozzan T., Lodovichi C. (2011). "Interplay among cGMP, cAMP, and Ca2+ in living olfactory sensory neurons in vitro and in vivo". The Journal of Neuroscience 23 (23): 8395–8405. doi:10.1523/JNEUROSCI.6722-10.2011. 
  5. ^ Stockman, A; Sharpe, LT; Tufail, A; Kell, PD; Ripamonti, C; Jeffery, G (June 2007). "The effect of sildenafil citrate (Viagra) on visual sensitivity" (Free full text). J Vis 7 (8): 4. doi:10.1167/7.8.4. PMID 17685811. 
  6. ^ Daugan, A; Grondin, P; Ruault, C; Le Monnier De Gouville, AC; Coste, H; Linget, JM; Kirilovsky, J; Hyafil, F; Labaudinière, R (October 2003). "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues". J Med Chem 46 (21): 4533–42. doi:10.1021/jm0300577. ISSN 0022-2623. PMID 14521415. 

See also[edit]